BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27815459)

  • 1. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
    Bühler H; Hoberg C; Fakhrian K; Adamietz IA
    In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
    Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
    Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells.
    Lan YC; Chang CL; Sung MT; Yin PH; Hsu CC; Wang KC; Lee HC; Tseng LM; Chi CW
    Anticancer Res; 2013 Sep; 33(9):3807-14. PubMed ID: 24023313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
    Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.
    Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I
    J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
    Denoyelle C; Hong L; Vannier JP; Soria J; Soria C
    Br J Cancer; 2003 May; 88(10):1631-40. PubMed ID: 12771933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
    Jia X; Cheng J; Shen Z; Shao Z; Liu G
    Mol Med Rep; 2018 Apr; 17(4):5470-5476. PubMed ID: 29393454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
    Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
    Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
    Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
    Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I
    Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
    Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
    Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
    Haider MT; Holen I; Dear TN; Hunter K; Brown HK
    Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer.
    Hashimoto K; Masumori N; Tanaka T; Maeda T; Kobayashi K; Kitamura H; Hirata K; Tsukamoto T
    Prostate; 2013 Apr; 73(5):500-11. PubMed ID: 22996996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
    Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
    Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
    Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
    Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
    Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.